Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 10/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30385007 | 1.00 | EGFR (0.39) | EGFRERBB2MAPTRECQLL3MBTL1 | |
| SCHEMBL17670162 | 0.95 | EGFR (0.39) | EGFRERBB2MAPTRECQLL3MBTL1 | |
| SCHEMBL17670287 | 0.93 | EGFR (0.44) | EGFRERBB2MAPTRECQLL3MBTL1 | |
| SCHEMBL31030290 | 0.93 | EGFR (0.44) | EGFRERBB2MAPTRECQLL3MBTL1 | |
| SCHEMBL17670135 | 0.90 | EGFR (0.35) | EGFRERBB2MAPTRECQLL3MBTL1 | |
| SCHEMBL31030279 | 0.89 | EGFR (0.37) | EGFRERBB2MAPTKMT2AKDR | |
| SCHEMBL17670296 | 0.89 | EGFR (0.37) | EGFRERBB2MAPTKMT2AKDR | |
| SCHEMBL17670231 | 0.87 | EGFR (0.51) | EGFRERBB2MAPTTDP1SMN1; SMN2 | |
| SCHEMBL17670292 | 0.85 | EGFR (0.36) | EGFRERBB2MAPTRECQLL3MBTL1 | |
| SCHEMBL34462033 | 0.84 | EGFR (0.38) | EGFRERBB2MAPTKMT2AKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725554-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2026-04-15 | — | — | EP | disclosed |
| US-RE50528-E1 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2025-08-12 | — | — | US | disclosed |
| EP-3929190-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2024-12-25 | — | — | EP | disclosed |
| EP-4421069-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2024-08-28 | — | — | EP | disclosed |
| CN-111686110-B | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2023-06-16 | — | — | CN | disclosed |
| EP-3929190-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2021-12-29 | — | — | EP | disclosed |
| EP-3604294-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2021-05-05 | — | — | EP | disclosed |
| CN-111686110-A | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2020-09-22 | — | — | CN | disclosed |
| CN-106795144-B | Compounds and compositions for modulating EGFR mutant kinase activity | 株式会社柳韩洋行 | 2020-06-16 | — | — | CN | disclosed |
| EP-3604294-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2020-02-05 | — | — | EP | disclosed |
| EP-3207035-B1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORP (KR) | 2019-11-20 | — | — | EP | disclosed |
| EP-3207035-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | Yuhan Corporation (KR) | 2017-08-23 | — | — | EP | disclosed |
| US-9593098-B2 | Compounds and compositions for modulating EGFR mutant kinase activities | YUHAN CORPORATION (KR) | 2017-03-14 | — | — | US | disclosed |
| WO-2016060443-A2 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORPORATION (KR) | 2016-04-21 | — | — | WO | disclosed |
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | YUHAN CORPORATION | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160102076-A1 | COMPOUNDS AND COMPOSITIONS FOR MODULATING EGFR MUTANT KINASE ACTIVITIES | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885MAPT 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.